Skip to content

US · ALXO · BIOTECHNOLOGY

ALX Oncology Holdings Inc. (ALXO) intrinsic value and stock valuation

$1.06as of 2026-11-21 · Mkt cap 258.36M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

ALX Oncology Holdings Inc. DCF and intrinsic value

InvestorsCraft values ALXO with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from ALXO’s statements →

ALX Oncology Holdings Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology South San Francisco, CA 94080 alxoncology.com

How the business is doing

Fiscal 2018–2025, USD

Revenue
$0.00
20182025
Net income
-$-101.69M
20182025
Free cash flow
-$-84.35M
20182025
Total equity
$26M-42.9% 5y CAGRd
20182025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2018–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-104.02M-$-142.47M-$-170.28M-$-127.44M-$-83.56M
Net income-$-101.69M-$-134.85M-$-160.81M-$-123.48M-$-83.46M
EPSd-$-1.9M-$-2.58M-$-3.74M-$-3.03M-$-2.07M
Operating cash flow-$-84.14M-$-121.91M-$-130.36M-$-89.22M-$-68.1M
Capital expenditure-$-210K-$-450K-$-1.27M-$-1.43M-$-4.92M
Free cash flow-$-84.35M-$-122.36M-$-131.64M-$-90.65M-$-73.02M
Total assets$59.1M$147.8M$242.6M$306.5M$380.2M
Total debt$5.22M$17M$17.2M$10.4M$740K
Net debt-$-11.16M-$-590K-$-5.21M-$-38.39M-$-362.93M
Total equity$26M$113.6M$189.7M$263.5M$363.1M
Cash and short-term investments$44.8M$127.8M$182.7M$266.2M$363.7M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00$0.00$0.00
Research and development expenses$77M$116.4M$141.8M$98.4M$60.2M
Selling, general and administrative expenses$23.9M$26.1M$28.5M$29M$23.4M
Other expenses$3.17M$0.00$0.00$0.00$0.00
Operating expenses$104M$142.5M$170.3M$127.4M$83.6M
Cost and expenses$104M$142.5M$170.3M$127.4M$83.6M
Interest income$3.96M$9.37M$10.7M$4.28M$0.00
Interest expense$1.6M$1.73M$1.56M$240K$10K
Depreciation and amortization$710K$870K$840K$340K$50K
Ebitda-$-99.39M-$-132.25M-$-158.4M-$-122.84M-$-83.42M
Operating income-$-104.02M-$-142.47M-$-170.28M-$-127.44M-$-83.56M
Total other income/expenses, net$2.33M$7.62M$9.47M$4.02M$70K
Income before tax-$-101.69M-$-134.85M-$-160.81M-$-123.42M-$-83.48M
Income tax expense$0.00$0.00$0.00$60K-$-20K
Net income-$-101.69M-$-134.85M-$-160.81M-$-123.48M-$-83.46M
Weighted average shares outstanding$53.7M$52.2M$43M$40.7M$40.3M
Weighted average diluted shares outstanding$53.7M$52.2M$43M$40.7M$40.3M
Balance sheet
20252024202320222021
Cash and short-term investments$44.8M$127.8M$182.7M$266.2M$363.7M
Net receivables$300K$890K$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$50.7M$134.4M$188.7M$271M$367M
Property, plant and equipment, net$1.2M$9.63M$10.8M$9.81M$3.47M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$3.49M$3.52M$35.4M$16.7M$0.00
Total non-current assets$8.32M$13.4M$53.9M$35.5M$13.2M
Total assets$59.1M$147.8M$242.6M$306.5M$380.2M
Accounts payable$4.91M$4.5M$8.59M$8.07M$3.76M
Short-term debt$5.22M$2.35M$1.57M$1.04M$740K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$24.6M$18.5M$36M$28.3M$15.3M
Long-term debt$0.00$14.6M$15.6M$9.39M$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$8.51M$15.7M$16.8M$14.7M$1.84M
Capital lease obligations$0.00$7.07M$7.56M$1.04M$740K
Total liabilities$33.1M$34.2M$52.8M$43M$17.1M
Common stock$50K$50K$50K$40K$40K
Retained earnings-$-722.82M-$-621.12M-$-486.27M-$-325.47M-$-201.99M
Accumulated other comprehensive income (loss)$30K$280K$260K-$-840K-$0.00
Total equity$26M$113.6M$189.7M$263.5M$363.1M
Total investments$31.9M$113.7M$195.7M$234.1M$0.00
Total debt$5.22M$17M$17.2M$10.4M$740K
Net debt-$-11.16M-$-590K-$-5.21M-$-38.39M-$-362.93M
Cash flow statement
20252024202320222021
Net income-$-101.69M-$-134.85M-$-160.81M-$-123.48M-$-83.46M
Depreciation and amortization$710K$870K$840K$340K$50K
Stock-based compensation$12.6M$27.1M$26.3M$23.8M$13.9M
Change in working capital$340K-$-12.43M$8.3M$9.85M-$-4.03M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$420K-$-4.02M$460K$4.51M$3.29M
Net cash provided by operating activities-$-84.14M-$-121.91M-$-130.36M-$-89.22M-$-68.1M
Investments in property, plant and equipment-$-210K-$-450K-$-1.27M-$-1.43M-$-670K
Acquisitions, net$0.00$0.00$0.00$230K$0.00
Net cash used for investing activities$82.6M$86.3M$44.7M-$-235.42M-$-4.92M
Common stock issued$1.73M$31.6M$58.9M$900K$2.75M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$360K$30.8M$59.3M$9.86M$2.47M
Net change in cash-$-1.19M-$-4.84M-$-26.42M-$-314.78M-$-70.55M
Cash at end of period$16.4M$17.6M$22.5M$48.9M$363.7M
Operating cash flow-$-84.14M-$-121.91M-$-130.36M-$-89.22M-$-68.1M
Capital expenditure-$-210K-$-450K-$-1.27M-$-1.43M-$-4.92M
Free cash flow-$-84.35M-$-122.36M-$-131.64M-$-90.65M-$-73.02M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About ALX Oncology Holdings Inc.

        ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company’s lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

        CEO
        Jason Lettmann
        Employees
        43
        Beta
        0.43

        Explore

        Frequently asked questions

        What is the intrinsic value of ALX Oncology Holdings Inc. (ALXO)?

        InvestorsCraft does not currently publish an intrinsic value for ALXO. How the IC value is calculated.

        Is ALXO undervalued?

        InvestorsCraft does not publish an undervaluation signal for ALXO at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.